查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1732961

肝炎診斷檢測市場－全球產業規模、佔有率、趨勢、機會和預測（按檢測類型、地區和競爭細分，2020-2030 年）

Hepatitis Diagnostic Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球肝炎診斷測試市場價值為 45.8 億美元，預計到 2030 年將達到 65.1 億美元，預測期內複合年成長率為 6.04%。全球性內肝炎（尤其是B型肝炎和C肝）的盛行率不斷上升，推動了對準確、及時的診斷解決方案的需求。根據世界衛生組織統計，2021 年全球有近 3.25 億人患有慢性肝炎，凸顯了對有效診斷干預措施的迫切需求。這個市場受到人們意識的提高、技術進步以及早期檢測以預防肝硬化和癌症等併發症的重要性的推動。各種檢測方法（包括血清學、分子檢測和肝功能檢測）的出現拓寬了診斷能力。此外，創新的即時檢驗（POCT）設備使診斷變得更加容易，特別是在偏遠或服務不足的地區。這些進步，加上政府措施和全球健康運動的加強，持續支撐市場的成長軌跡。

市場概覽
預測期 2026-2030
2024年市場規模 45.8億美元
2030年市場規模 65.1億美元
2025-2030 年複合年成長率 6.04%
成長最快的領域 血液檢查
最大的市場 北美洲

關鍵市場促進因素

全球肝炎負擔不斷上升

主要市場挑戰

高昂的診斷費用

主要市場趨勢

即時檢驗 (POCT)

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球肝炎診斷檢驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依測試類型（血液檢查、影像學檢查、肝臟活體組織切片）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 產品市場圖
    • 按測試類型
    • 按地區

第6章：北美肝炎診斷檢驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肝炎診斷檢驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肝炎診斷檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章：南美洲肝炎診斷檢驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲肝炎診斷測試市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購
  • 產品開發
  • 最新動態

第 13 章：波特的分析

第 14 章：PESTEL 分析

第 15 章：競爭格局

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen NV
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 16280

The Global Hepatitis Diagnostic Test Market was valued at USD 4.58 billion in 2024 and is projected to reach USD 6.51 billion by 2030, growing at a CAGR of 6.04% during the forecast period. The increasing global prevalence of hepatitis, particularly Hepatitis B and C, is driving demand for accurate and timely diagnostic solutions. According to the World Health Organization, nearly 325 million individuals globally were living with chronic hepatitis in 2021, highlighting the urgent need for effective diagnostic interventions. This market is fueled by heightened awareness, technological advancements, and the importance of early detection to prevent complications like liver cirrhosis and cancer. The availability of various testing methods-including serology, molecular assays, and liver function tests-has broadened diagnostic capabilities. Furthermore, innovative point-of-care testing (POCT) devices are making diagnostics more accessible, especially in remote or underserved regions. These advancements, combined with increased government initiatives and global health campaigns, continue to bolster the market's growth trajectory.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.58 Billion
Market Size 2030USD 6.51 Billion
CAGR 2025-20306.04%
Fastest Growing SegmentBlood Tests
Largest MarketNorth America

Key Market Drivers

Rising Global Hepatitis Burden

The growing prevalence of hepatitis infections worldwide is a major force driving the Hepatitis Diagnostic Test Market. According to WHO, in 2023, approximately 60 million individuals in the South-East Asia region alone were living with chronic hepatitis B. Global transmission is often exacerbated by unsafe medical practices, lack of clean water and sanitation, and insufficient access to healthcare. Compounding this issue is the silent nature of hepatitis, which frequently progresses without symptoms until advanced liver damage has occurred. Early and accurate diagnosis is thus critical to preventing severe health outcomes such as cirrhosis and liver cancer. Governments and healthcare organizations are ramping up national screening programs and awareness campaigns, encouraging regular testing for high-risk populations including healthcare workers, people living with HIV, and intravenous drug users. These efforts are significantly expanding access to diagnostic services and promoting timely medical intervention.

Key Market Challenges

High Diagnostic Costs

A major challenge in the Hepatitis Diagnostic Test Market is the high cost associated with testing, particularly for molecular diagnostics such as PCR. These tests require specialized reagents, sophisticated equipment, and skilled laboratory personnel, which collectively drive up costs. This is especially burdensome in low-resource settings or among uninsured populations, where affordability becomes a barrier to widespread testing. Operational expenses tied to equipment maintenance, laboratory infrastructure, and quality assurance further increase the cost of diagnosis. Moreover, patients often require multiple tests to monitor disease progression and treatment efficacy, adding to the financial burden. In regions where insurance coverage is limited or inconsistent, out-of-pocket costs may deter individuals from undergoing necessary diagnostic evaluations.

Key Market Trends

Point-of-Care Testing (POCT)

Point-of-care testing is emerging as a transformative trend in hepatitis diagnostics. These compact, portable devices allow for rapid testing outside traditional laboratory environments, greatly enhancing diagnostic reach in rural and underserved areas. POCT minimizes the need for specialized equipment and skilled personnel, enabling quick, onsite diagnosis that facilitates timely treatment initiation. This immediacy not only improves patient outcomes but also helps curb the transmission of hepatitis within communities. The accessibility and speed of POCT make it a practical solution for widespread screening efforts, particularly in primary care settings and mobile health units. As healthcare providers seek more efficient and decentralized diagnostic methods, the adoption of POCT is expected to accelerate, driving market innovation and growth.

Key Market Players

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen N.V.
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

Report Scope:

In this report, the Global Hepatitis Diagnostic Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis Diagnostic Test Market, By Test Type:

  • Blood Tests
  • Imaging Test
  • Liver Biopsy

Hepatitis Diagnostic Test Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis Diagnostic Test Market.

Available Customizations:

Global Hepatitis Diagnostic Test market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis Diagnostic Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Blood Tests, Imaging Test, Liver Biopsy)
      • 5.2.1.1. By Blood Tests (Liver Function Tests, Immunoassays, Nucleic Acid Tests)
    • 5.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.3. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By Region

6. North America Hepatitis Diagnostic Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis Diagnostic Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
    • 6.3.2. Canada Hepatitis Diagnostic Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
    • 6.3.3. Mexico Hepatitis Diagnostic Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type

7. Europe Hepatitis Diagnostic Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatitis Diagnostic Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
    • 7.3.2. France Hepatitis Diagnostic Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
    • 7.3.3. United Kingdom Hepatitis Diagnostic Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
    • 7.3.4. Italy Hepatitis Diagnostic Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
    • 7.3.5. Spain Hepatitis Diagnostic Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type

8. Asia-Pacific Hepatitis Diagnostic Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hepatitis Diagnostic Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
    • 8.3.2. Japan Hepatitis Diagnostic Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
    • 8.3.3. India Hepatitis Diagnostic Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
    • 8.3.4. South Korea Hepatitis Diagnostic Test Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
    • 8.3.5. Australia Hepatitis Diagnostic Test Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type

9. South America Hepatitis Diagnostic Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hepatitis Diagnostic Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
    • 9.3.2. Argentina Hepatitis Diagnostic Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
    • 9.3.3. Colombia Hepatitis Diagnostic Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type

10. Middle East and Africa Hepatitis Diagnostic Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Hepatitis Diagnostic Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
    • 10.3.2. Saudi Arabia Hepatitis Diagnostic Test Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
    • 10.3.3. South Africa Hepatitis Diagnostic Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc
  • 15.3. F. Hoffmann-La Roche AG
  • 15.4. BioMerieux SA
  • 15.5. Siemens Healthineers
  • 15.6. Qiagen N.V.
  • 15.7. Grifols SA
  • 15.8. Fujirebio Inc.
  • 15.9. Molbio diagnostics Pvt. Ltd
  • 15.10. Meril LifeSciences Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimers